Northwest Biotherapeutics’ DCVax-L Chosen for New UK Fast-Track Access Scheme

Northwest Biotherapeutics’ new experimental cancer jab, DCVax-L, is the first medicine to be approved by the UK’s new fast-track access programme for early use. The cell therapy has received ‘Promising Innovative Medicine’ (PIM) designation, which is the initial step in the new Early Access to Medicines Scheme (EAMS). The cancer jab ‘retrains’ a patient’s immune

Continue Reading